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The prevalence of nontuberculous mycobacteria (NTM) is high (ap- function (1). However, the impact of these organisms on the
proximately 13%) in sputum of patients with cystic fibrosis (CF), clinical course of CF lung disease has not been prospectively
but the impact on lung disease is unknown. We followed 60 incident evaluated.
NTM-positive and 99 culture-negative patients with CF for 15 Criteria for the diagnosis of disease caused by NTM in
months and assessed clinical impact of NTM by FEV1 and high- persons without CF have been published (2). Diagnosis re-
resolution computed tomography (HRCT) of the chest. Mycobacte- quires the presence of (1) clinical signs and symptoms; (2)
rium avium complex was seen in 75% of NTM-positive subjects. The multiple positive sputum cultures, recovery of NTM in large
annual rate of decline in FEV1 was not different among control amounts on microbiologic smears and cultures of broncho-
versus NTM-positive subjects who did not, or did, meet American scopic samples, and/or compatible histopathology with a posi-
Thoracic Society microbiologic criteria for NTM disease (3  1, 3  tive NTM culture; and (3) compatible radiographic findings.
2, and 5  2%, respectively). More subjects with three or more
Defining NTM disease in patients with CF is particularly chal-positive cultures for NTM had two or more characteristic findings
lenging, given the considerable overlap of the clinical and ra-on entry HRCT (60%, 9/15) as compared with subjects with two
diographic criteria between disease caused by NTM and CF.positive cultures or less (32%) or negative cultures (19%; p  0.02).
Although case reports of an apparent association betweenAll subjects with three or more positive cultures and exit HRCTs
NTM and a decline in clinical and radiographic features have(n  6) showed progression of HRCT findings, whereas only 17%
been published, other reports of this relationship suggestof subjects with two positive cultures or less had progression (p 
these organisms may coexist in the lower airways of some0.0006). In summary, no significant short-term effect on FEV1 was
subjects with CF without significant adverse effect (3–13).detected in patients with multiple positive NTM cultures, but an
abnormal HRCT was predictive of progression. Patients with CF There has been no prospective, rigorous evaluation of the
and multiple positive NTM cultures, characteristic HRCT findings, and impact of NTM in the lower airways on lung function, and
progression of HRCT changes should be monitored closely and radiographic findings of the presence of NTM in CF have
considered for antimycobacterial therapy. not been published. This study was designed to look systemat-
ically at the (short-term) longitudinal effects of NTM on the
Keywords: cystic fibrosis; nontuberculous mycobacteria; Mycobacte- clinical course of CF lung disease, as assessed by changes in
rium avium-intracellulare; Mycobacterium abscessus; computed tomogra- spirometry and chest computed tomography (CT), to develop
phy of chest
criteria that may indicate a need for further diagnostic evalua-
tion and/or initiation of specific antimycobacterial therapy.The prevalence of nontuberculous mycobacteria (NTM) in
the lower respiratory tract of older subjects with cystic fibrosis
METHODS(CF) is high (approximately 13%) relative to the background
population and to other disease groups. We reported, in a Study Design
cross-sectional study, an increase in the prevalence of NTM
A previous multicenter cross-sectional study assessed prevalence ofwith age and an association with relatively preserved lung
NTM (1) in three sputum samples over a year. The current nested-
cohort design identified incident NTM-positive subjects (at least one
prior negative culture) from the prevalence study (Figure 1), matched
by age, sex, and FEV1 to two culture-negative “controls” in that study
(Figure 1). Subjects were followed for 15 months, and sputum was(Received in original form July 9, 2002; accepted in final form November 6, 2002)
tested on each visit. Chest radiographs were performed at entry, 6, and
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15 months; chest HRCT was performed at entry and 15 months on
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NTM-positive subjects and 20% of the control subjects.
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NTM-positive subjects were categorized by American Thoracic So-
ciety (ATS) microbiologic criteria for disease; subjects with three or
more positive cultures, or two positive cultures and a positive smear,
“met criteria,” but subjects with two positive cultures or less “did not
meet criteria.” Univariate comparisons of control subjects versus the
two groups of NTM-positive subjects (“meeting” and “not meeting”
criteria) were assessed by analysis of variance for baseline characteris-
tics, days of hemoptysis, corticosteroid and intravenous antibiotic use,
and microbiology. Chest radiograph scores were assessed by multivari-
ate analysis of variance (control subjects vs. two groups of NTM-sub-
jects) versus NTM status and time. Differences in baseline and serial
HRCT findings were assessed by Fisher’s exact test.
We used mixed linear regression models to test whether FEV1 de-
cline was different between NTM-positive subjects and control subjects
and among NTM-positive subjects who did, or did not, meet microbio-
logic criteria (23). The first model used data collected at the beginning
of the previous prevalence study and during this current study, including
covariates (age, sex, and body mass index). The second model covered
Figure 1. Timeline depicting the relationship between the previous only data from entry into this study (Figure 1), including additional
cross-sectional, prevalence study and this current nested-cohort study, covariates (FEV1, corticosteroids, and parenteral antibiotics). The effectwhich was performed in subjects identified by the prevalence study. of NTM status on FEV1 was tested by comparing two models using
Subjects with least one negative acid fast bacillus (AFB) culture in the log-likelihood statistics. Pairwise differences were assessed between the
prevalence study were entered into the current (nested-cohort) study two categories of NTM-positive subjects and control subjects.
at the time of their first positive AFB culture and were matched to two
subjects who were NTM-culture–negative. Both NTM-positive subjects RESULTS
and their matched, culture-negative control subjects were assessed clini-
cally every 3 months for 15 months with specimens for mycobacterial Baseline Characteristics
culture obtained at each visit. Sixty NTM-positive and 99 control subjects were enrolled from
17 U.S. CF centers (Table 1). Although NTM-positive subjects
tended (p  0.16) to be slightly older (average, 2 years) than
control subjects at entry into the cohort study, they also tendedreference laboratory (University of Texas Health Center, Tyler, TX)
to have higher FEV1 values (approximately 5%, p  0.19) andfor final identification.
slightly better Birmingham Composite Radiograph Scores (ap-
Radiographic Evaluation proximately 1.0; p  0.08). The chest CT findings tended to
parallel the pattern seen with FEV1 values and BirminghamOriginal radiographs (posteroanterior and lateral chest) were scored
Radiograph Scores. Specifically, more NTM-positive subjectsat Chapel Hill (Birmingham Roentgenogram Score) (19). HRCT scans
were performed at respective sites and evaluated in Chapel Hill tended to have at least two chest CT findings that are characteris-
(P.L.M.) without knowledge of culture status. HRCTs were assessed tic of NTM disease in subjects without CF as compared with
for four characteristic findings associated with NTM in subjects without control subjects (p  0.11) (see further comments below). There
CF: (1 ) cystic and/or cavitary parenchymal lung disease, (2 ) subsegmen- were no significant differences in sex, body mass index, or the
tal (or larger) parenchymal consolidation, (3 ) single or multiple pulmo- frequency of pancreatic enzyme use.
nary nodules, and (4 ) tree-in-bud opacities (20–22).
Mycobacterial Cultures
Statistical Analysis
Control subjects had 7.8  0.1 (range 4–11) cultures, and NTM-Descriptive statistics were used to identify differences between NTM-
positive subjects had 8.9  0.2 (range 5–13) cultures over 16positive and control (NTM-negative) subjects. The 2 test was used to
months. Before the first positive culture, 23 (38%) of NTM-compare categoric characteristics at baseline between NTM-positive
positive subjects had one negative culture, 19 (32%) had twoand control subjects, and two-tailed Student’s t tests (independent)
were used for continuous variables. negative, and 18 (30%) had three or more negative cultures.
TABLE 1. COMPARISON OF NONTUBERCULOUS MYCOBACTERIA–POSITIVE SUBJECTS AND
NONTUBERCULOUS MYCOBACTERIA–NEGATIVE CONTROL SUBJECTS AT ENTRY INTO THE
NESTED-COHORT STUDY
NTM-Positive Subjects Control Subjects
Characteristic (n  60) (n  99) p Value*
Sex, % male 48 45 0.72
Age at enrollment, yr, mean 28.5  1.4 26.2  0.9 0.16
FEV1, % predicted, mean 57.6  2.9 52.8  2.2 0.19
Body mass index, kg/m2, mean 20.7  0.4 20.0  0.3 0.18
Use of pancreatic enzymes, % 95 95 0.99
Birmingham Radiograph Score, mean† 17.6  0.5 16.6  0.3‡ 0.08
Characteristic CT findings, %§‖ 40 19 0.11
Definition of abbreviations: CT  computed tomography; NTM  nontuberculous mycobacteria.
* 2 for dichotomous variables, and t test for continuous variables.
† Composite score.
‡ n  96.
§ At least two of the following features: cysts/cavities, consolidation, nodules, tree-in-bud.
‖ Subjects with entry CT scans: cases, n  53; control subjects, n  21.
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Figure 2. The number of subjects having positive mycobacterial cul-
tures, grouped by mycobacterial species. The bars represent the number
of subjects who did not meet the ATS microbiologic criteria for NTM
disease (hatched bars, lower stacks) and those subjects who did meet
ATS criteria (solid bars, upper stacks).
The majority of NTM-positive subjects had only a single positive
culture (n  34, 57%) with only two of these having a positive
smear; eight (13%) had two positive cultures, four of whom had
positive smears; eight (13%) had three positives with half having
positive smears; and 10 (17%) had more than three positive
Figure 3. Potential clinical variables that may confound the relationshipcultures with half having at least one positive smear. Of the 60
between NTM and decline in %FEV1 (% predicted), plotted by groupsNTM-positive subjects, 22 (37%) met the ATS microbiologic
of subjects (open bars, control subjects; hatched bars, NTM-positivecriteria for NTM disease.
subjects who did not meet ATS criteria; solid bars, NTM-positive subjectsMycobacterium avium complex (MAC) was recovered from
who met ATS microbiologic criteria for disease). (A) Presence of hemop-the majority of the NTM-positive subjects (n  45, 75%) with
tysis and use of systemic steroids and parenteral antibiotics (*p  0.05,a third (14) of these meeting ATS criteria (Figure 2). Mycobacte-
less than culture-negative control subjects. ‡p  0.05, greater than
rium abscessus was recovered from seven subjects (12%), and NTM-positive subjects). (B) Sputum microbiology (*p  0.02, greater
four of those met ATS microbiologic criteria. Subjects with M. than culture-negative control subjects and NTM-positive subjects who
abscessus tended to meet ATS NTM criteria more frequently did not meet ATS criteria).
than subjects with MAC or other NTM organisms (odds ratio 
3.2, 95% confidence interval 0.8, 12.9; p  0.1). One subject
had three different organisms—M. abscessus, Mycobacterium
kansasii, and Mycobacterium malmoense; three subjects had both not control for differences in baseline FEV1. The decline in FEV1
MAC and M. abscessus; one subject had both MAC and Myco- was modest but significantly different from zero for all three
bacterium gordonae (multiple isolates); and one had Mycobacte- groups. However, there was no significant difference in the mean
rium pergrinum, one had Mycobacterium lentiflavum, and one annual decline in FEV1 (% predicted) among the three groups
had M. kansasii (Figure 2). (1.9  0.4%, 1.2  0.6%, and 2.4  0.7%, respectively). The
second analysis (Model 2) controlled for differences in baselineClinical Variables
FEV1 and the use of parenteral antibiotics and systemic cortico-
There was no significant difference in the number of days with steroids, in addition to the variables controlled for in the initial
hemoptysis among the control subjects and NTM-positive sub- analysis. Again, there was no significant difference among the
jects that either did not, or did, meet ATS microbiologic criteria groups (3.2  1.1%, 3.1  1.8%, and 4.7  2.4%, respectively)
(Figure 3A). Steroids were used less frequently in the NTM- (Figure 4).
positive subjects who met ATS criteria as compared with the
Radiologic AssessmentNTM-negative control group (p  0.05). Intravenous antibiotics
were used more frequently in the control group compared with Baseline and follow-up chest radiographs were available for
the NTM-positive subjects (p  0.05, Figure 3A). There were analysis on 53 (54%) of the control subjects, 26 (68%) of the
no significant differences among the three groups in the recovery non-ATS criteria NTM-positive subjects, and 10 (45%) of the
of Pseudomonas aeruginosa or Aspergillus species during the ATS criteria NTM-positive subjects. There was no significant
course of follow-up (Figure 3B). Staphylococcus aureus was re- change over time in any of the chest radiograph scores (individ-
covered from sputum more frequently in NTM-positive subjects ual category and composite) within either control subjects or
who met ATS microbiologic criteria than in NTM-positive sub- the two groups of NTM-positive subjects or between the two
jects who did not meet ATS criteria and in control subjects (p  culture-positive groups.
0.01) (Figure 3B). Entry HRCTs were available for analysis on 53 (88%) of
the NTM-positive subjects and 21 (21%) of the control (NTM-
Longitudinal Decline in Lung Function negative) subjects; exit CTs were available on 24 and 8 of these
The initial analysis (Model 1) included FEV1 data collected from two groups, respectively. Overall, the four characteristic findings
the prior cross-sectional study and compared control subjects, associated with NTM disease were more prevalent among the
NTM-positive subjects who did not meet ATS criteria and NTM- NTM-positive subjects who met ATS criteria than NTM-positive
positive subjects who met criteria. This initial model controlled subjects who did not meet ATS criteria and in the control sub-
jects (Figure 5). Two or more of these HRCT findings werefor three key variables (sex, age, and body mass index) but did
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served lung function. Anecdotal reports of these organisms coex-
isting in the airways of subjects with CF over prolonged periods
without apparent adverse effect are interspersed with reports of
precipitous declines in clinical status, which are temporally re-
lated to acquisition of NTM (3–13). The goal of this study was
to assess the effect of these organisms on the short-term clinical
course of CF lung disease. We identified subjects early in their
acquisition of NTM and matched them to culture-negative sub-
jects in an attempt to assess changes in lung function and chest
HRCT scans more likely to be related to NTM and less likely
related to some confounding variable. At entry into this cohort
study these subjects remained well matched, except for a slightly
lower %FEV1 in the control subjects (Table 1).Figure 4. Annual decline in FEV1 (% predicted) based on mixed model
analyses, which shows control subjects (open bars), NTM-positive sub- To better assess the effect of NTM on the clinical course of
jects who did not meet ATS microbiologic criteria (hatched bars), and CF, we grouped the NTM-positive subjects according to the ATS
NTM-positive subjects who met ATS criteria (solid bars). This analysis microbiologic criteria for disease. As reported in the previous
(Model 2) incorporated only FEV1 data collected after the entry visit prevalence study (1), the majority of the NTM-positive subjects
into this current study, controlled for differences in baseline FEV1, and the had only one positive culture or two positive cultures without
use of systemic corticosteroids and intravenous antibiotics, in addition to smear positivity, and thus did not meet the ATS microbiologic
variables in Model 1 (see METHODS). criteria for disease. Subjects from whom M. abscessus was cul-
tured tended to meet microbiologic criteria more frequently than
did those with only MAC or other NTM (Figure 2). Subjects
who met the microbiologic criteria for NTM were not sickerpresent at baseline (entry) in a greater fraction (60%, n  9)
than either those subjects not meeting criteria or those whoof the 15 subjects with three or more positive cultures as com-
remained culture-negative (controls), as assessed by frequencypared with 32% of those subjects with only one or two positive
of hemoptysis, corticosteroid use, intravenous antibiotic use, orcultures and 19% of NTM-negative, control subjects (p  0.02).
prevalence of P. aeruginosa (Figure 3A). Although patients withComparable differences were noted when analyses included only
mycobacteria tended to have a higher reported prevalence ofsubjects with MAC and M. abscessus. More subjects who met
Aspergillus than did culture-negative control subjects, there wasATS criteria and had significant baseline CT findings, and who
no difference in Aspergillus prevalence based on ATS microbio-also had exit CTs, had progression of CT findings, as compared
logic criteria. As reported in the previous prevalence study, awith the other subjects with entry and exit CTs. Progression of
strikingly higher prevalence of S. aureus was seen in those NTM-CT findings was noted in only 3 of 8 (38%) control subjects,
positive patients who met ATS criteria as compared with NTM-and 4 of 18 (22%) non-ATS criteria NTM-positive subjects,
positive subjects who did not meet ATS criteria and controlwhereas all 6 (100%) of the subjects with three or more positive
subjects (p  0.02) (Figure 3B).cultures had progression (p  0.0006).
We tested for change (decline) in FEV1 over time to assess
the potential effect of NTM on the course of CF lung disease.
DISCUSSION Different models were constructed to control for both key clini-
cal variables and potential confounders. Although NTM-positiveWe have previously reported a high prevalence of NTM (approx-
subjects who met ATS criteria tended to decline faster thanimately 13%) in sputum of persons with CF lung disease. This
both the non–ATS-positive and control subjects, the amount ofprevalence is most striking in older subjects with relatively pre-
variability in the slope estimates was large, and no statistically
significant differences in the slopes was detected. The rate of
decline in FEV1 in the CF control subjects was similar to what
has been noted in other studies of similar age patients with
CF (1–3% per year) (24). There are examples in the literature
suggesting a probable adverse effect of NTM on lung function.
Some of those indicate a precipitous decline temporally related
to recovery of NTM (4, 6, 7), whereas others note a prolonged
time span between initial recovery and subsequent adverse ef-
fects (9, 12). Perhaps more significant differences in FEV1 would
be seen with a longer duration of follow-up. For example, we
estimated that significant differences would be seen between
NTM-positive subjects who met ATS criteria versus control sub-
jects if the slopes declined (Figure 4) at similar rates for 6.4
years.
Given the many factors that can affect the change in FEV1Figure 5. Characteristic HRCT findings in control subjects and NTM- over relatively short periods of time in patients with CF, airflow
positive subjects by culture status at entry (solid bars) into the study.
mechanics may not be the most sensitive or specific indicator ofSolid bars represent the percent of subjects in each of the three sub-
disease progression related to a specific microorganism, such asgroups with at least two of the following characteristics on entry HRCT:
the NTM. Several studies have suggestive characteristic findings(A ) areas of cystic and/or cavitary parenchymal lung disease, (B ) subseg-
on HRCT scan in patients with NTM and without CF (20–22).mental or larger areas of parenchymal consolidation, (C ) single or multi-
More recent studies have also demonstrated progression of theseple pulmonary nodules, and (D ) tree-in-bud opacities. More of the NTM
findings over relatively short periods of time; one study notedpositive subjects who met ATS Criteria had at least two of these findings
progression at a mean follow-up of 28  4 months and anotherat entry as compared with control subjects and subjects with only one
or two positive cultures at entry (*p  0.02). at 28  13 (range 12–42) months (25, 26). The characteristic
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HRCT findings associated with NTM include cysts or cavities,
segmental consolidation, peripheral nodules, and tree-in-bud
type infiltrates. Although these radiographic findings may over-
lap with those commonly seen in CF, the relative frequency of
these findings was higher in patients with CF who met ATS
microbiologic criteria for NTM disease, even though their FEV1
values were similar to those of subjects with only one or two
positive NTM cultures and culture-negative control subjects.
Moreover, all six of the NTM-positive subjects who had three
or more positive NTM cultures as well as both entry and exit
HRCT scans had progression of at least one of the four HRCT
findings. In contrast, only 4 subjects out of 18 with only one or
two positive cultures had these HRCT changes. This suggests
that HRCT may play a vital role in the evaluation of subjects
with CF and with positive NTM sputum cultures and may be an
earlier indicator than FEV1 of pathogenic infection with NTM;
however, additional study will be required for confirmation.
The study was limited by sample size and length of follow-
up. Sample size calculations were based on comparison of rate
of change in FEV1 for all NTM-positive subjects versus their
matched culture-negative control subjects. Given the sampling
variability in recovering NTM coupled with the significant
Figure 6. Flow diagram of proposed clinical approach to finding NTMHRCT findings on the entry scan of subjects who eventually
in the lower airway of a patient with CF (see text for details). Furthermet ATS microbiologic criteria, it is likely that some subjects
study is needed to validate this approach.entered the study after having had NTM in their airways for a
period of time and thus were prevalent rather than incident
positives. A relatively large number of subjects originally classi-
fied as culture-negative control subjects converted to NTM cul- M. abscessus, consideration should be given to beginning specific
ture-positive, but it is less likely that subjects were misclassified antimycobacterial treatment, particularly if there is a temporally
as control subjects in the final analyses, given the large numbers associated decline in the clinical course; this approach is based
of cultures obtained. Finally, both the revised ATS criteria for on prior reports associating this organism with significant disease
NTM pulmonary disease and longitudinal studies of the length in CF, (3, 5, 8, 10, 12). If the organism is not M. abscessus, or
of time for progression of HRCT findings in patients without if characteristic HRCT findings are not present, and the patient
CF and with nodular bronchiectatic disease were published after is clinically stable, a follow-up HRCT should be obtained in 12
the initiation of this investigation (2, 25, 26). It seems unlikely to 15 months, while continuing to collect serial sputum specimens
that NTM would have the same impact in subjects with a single for mycobacterial culture. If progression of the characteristic
positive culture out of multiple specimens as compared with findings on HRCT is seen and the patient continues to have
those subjects who had multiple positive cultures, and this notion positive cultures of the same NTM organism, consideration
was borne out in preliminary analyses. Thus, we believed it should be given to specific antimycobacterial treatment. If
appropriate to group the NTM-positive subjects, based on the HRCT progression is not noted, continued follow-up with serial
ATS microbiologic criteria for disease, to test the clinical impact HRCT scans and cultures should be performed to monitor for
of NTM. progression. Given the overlapping coverage of many of the
Despite these limitations, this study is compatible with the drugs used to treat NTM with usual CF pathogens such as P.
general clinical approach that is evolving to address the presence aeruginosa and S. aureus, airways clearance measures should be
of NTM recovered from the sputum of patients with CF intensified, and (other) bacterial lower airway pathogens should
(Figure 6). It should be noted that this current approach is based, be treated aggressively to establish a clinical baseline, before
in part, on the clinical experience that has been developed in starting specific antimycobacterial treatment, so that the effect
the context of NTM in the respiratory tract of individuals with of treatment on mycobacterial disease can be better assessed.
non-CF lung disease. Specifically, given the increasing preva- In summary, the presence of NTM in the lower airways is
lence of NTM with age (1) and case reports noting the potential common among persons with CF. The majority of persons from
for these organisms to cause significant clinical decline, adult whom NTM are recovered will have only a single isolate with
patients with CF should have periodic screening cultures. During repeated cultures obtained over one to two years. On the basis
periods of clinical decline unresponsive to treatment of conven- of trends in lung function seen in this study, those persons from
tional bacterial pathogens, all patients with CF, including chil- whom repeated positive cultures are obtained may be at risk of
dren, should be cultured for NTM. If a positive culture for an adverse effect on lung function over a period of months to
NTM is obtained, serial specimens should be collected to assess several years. Longer studies of serial lung function would be
frequency of recovery of the same species of NTM. If the ATS needed to confirm this. Characteristic HRCT findings of cysts
microbiologic criteria for NTM are met, and especially if three or cavities, areas of consolidation, peripheral nodules, or tree-
or more cultures are positive for the same species of NTM, a in-bud infiltrates are more prevalent in subjects with CF with
baseline HRCT scan should be obtained and assessed for the repeated positive cultures, and these findings may progress over
presence of (at least two of the four) characteristic findings of even a relatively short period of 12 to 15 months. Given the
NTM, described previously. If the ATS microbiologic criteria large number of confounding factors influencing the course of
are not met, periodic follow-up cultures should be obtained to CF lung disease and the relative general indolent nature of these
look for increasing prevalence of the organisms. For M. ab- organisms, further validation of the clinical approach described
scessus, if baseline HRCT findings are suggestive of mycobacte- previously and assessment of the effectiveness of treating these
organisms in CF will require longer-term studies.rial disease and the patient has repeated positive cultures for
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